Weiss Ratings Reaffirms Buy (B-) Rating for ADMA Biologics (NASDAQ:ADMA)

Key Points

• Weiss Ratings has reaffirmed a "buy (B-)" rating for ADMA Biologics, indicating continued confidence in the stock's potential.
• ADMA Biologics reported a quarterly earnings per share (EPS) of $0.15, beating analysts' estimates and showing a year-over-year revenue increase of 13.8%.
• Institutional investors currently hold 75.68% of ADMA Biologics' stock, with notable increases in holdings from several hedge funds during the second quarter.

ADMA Biologics (NASDAQ:ADMA - Get Free Report)'s stock had its "buy (b-)" rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

ADMA Biologics Stock Performance

ADMA stock traded up $0.31 during midday trading on Wednesday, reaching $14.30. 1,675,566 shares of the company's stock traded hands, compared to its average volume of 3,149,927. ADMA Biologics has a 52-week low of $13.50 and a 52-week high of $25.67. The stock has a market cap of $3.41 billion, a P/E ratio of 16.60 and a beta of 0.47. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The stock's 50-day moving average is $16.59 and its 200 day moving average is $18.66.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm's revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.13 earnings per share. As a group, analysts anticipate that ADMA Biologics will post 0.51 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC boosted its position in shares of ADMA Biologics by 114.1% during the second quarter. Corient Private Wealth LLC now owns 77,416 shares of the biotechnology company's stock worth $1,410,000 after acquiring an additional 41,260 shares during the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of ADMA Biologics by 70.7% during the second quarter. Orion Porfolio Solutions LLC now owns 64,587 shares of the biotechnology company's stock worth $1,176,000 after acquiring an additional 26,759 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of ADMA Biologics by 78.1% during the second quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company's stock worth $60,373,000 after acquiring an additional 1,453,924 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of ADMA Biologics during the second quarter worth $404,000. Finally, Ranger Investment Management L.P. boosted its position in shares of ADMA Biologics by 49.1% during the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company's stock worth $43,529,000 after acquiring an additional 786,865 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.